1. Ferraro S et al. Serum Human Epididymis Protein 4 vs Carbohydrate Antigen 125 for ovarian cancer diagnosis. A systematic review. J Clin Pathol 2013;66(4):273-81.
2. Gorp TV et al. HE 4 and CA 125 as a diagnostic testin ovarian cancer: prospective validation of the Risk of Ovarian Cancer Algorithm. Br J Cancer 2011;104(5):863-70
3. Campbell S, Bhan V, Royston J et al. Screening for early ovarian cancer. Br J Obstet Gynaecol 1986;93:1286-9
4. van Nagell JR et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 2007;109(9):1887-96.
5. Skates SJ, Xu FJ, Yu YH et al. Toward an optimal algorithm for ovarian cancer: a pilot randomised controlled trial. Cancer 1995; 76:Suppl:2004-10
6. Jacobs IJ et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 2016;387:945-56.
7. Vergote I et al. Neoadjuvant chemotherapy or primary surgery in Stage IIIC or IV Ovarian Cancer. N Engl J Med 2010;363:943-53.
8. Aghajanian C et al. OCEANS: A randomized, double-blind, placebo-controlled Phase III Trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer. J Clin Oncol 2012;30:2039-45.
9. Perren TJ et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med 2011;365:2484-96.
10. Disis ML et al. Effect pf dose on immune response in patients vaccinated with an ER-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004;22:1916-1925.